Christine Pien

4.8k total citations · 2 hit papers
23 papers, 3.7k citations indexed

About

Christine Pien is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, Christine Pien has authored 23 papers receiving a total of 3.7k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Molecular Biology, 7 papers in Oncology and 5 papers in Immunology. Recurrent topics in Christine Pien's work include Ubiquitin and proteasome pathways (14 papers), Axon Guidance and Neuronal Signaling (4 papers) and Cancer-related Molecular Pathways (4 papers). Christine Pien is often cited by papers focused on Ubiquitin and proteasome pathways (14 papers), Axon Guidance and Neuronal Signaling (4 papers) and Cancer-related Molecular Pathways (4 papers). Christine Pien collaborates with scholars based in United States, Germany and Spain. Christine Pien's co-authors include Peter J. Elliott, Julian Adams, Vito J. Palombella, Antonia T. Destree, Jochen Maas, Edward A. Sausville, Douglas Lazarus, J I Johnson, Steven L. Soignet and Teresa A. McCormack and has published in prestigious journals such as Journal of Clinical Investigation, Journal of Clinical Oncology and Blood.

In The Last Decade

Christine Pien

22 papers receiving 3.5k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Proteasome inhibitors: a novel class of potent and effective antitumor agents.

1999 1.2k citations Julian Adams, Vito J. Palombella et al. PubMed profile →
Phase I Trial of the Proteasome Inhibitor PS-341 in Patients With Refractory Hematologic Malignancies

2002 586 citations Robert Z. Orlowski, Thomas E. Stinchcombe et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Christine Pien United States	14	2.8k	1.5k	1.3k	437	331	23	3.7k
Kensuke Kojima Japan	29	1.8k 0.6×	1.1k 0.7×	959 0.7×	283 0.6×	327 1.0×	135	2.9k
Sonia Vallet United States	31	1.8k 0.6×	1.5k 1.0×	1.4k 1.0×	239 0.5×	345 1.0×	104	3.3k
John F. Lyons United States	32	2.7k 1.0×	1.3k 0.9×	577 0.4×	551 1.3×	347 1.0×	81	4.3k
Laurence Catley United States	30	2.9k 1.0×	1.4k 1.0×	2.3k 1.7×	303 0.7×	519 1.6×	59	4.0k
Boris K. Lin United States	26	2.8k 1.0×	1.6k 1.1×	2.4k 1.8×	241 0.6×	485 1.5×	50	4.4k
Ruben D. Carrasco United States	26	2.4k 0.9×	1.3k 0.9×	1.2k 0.9×	568 1.3×	889 2.7×	64	3.8k
Ronan Swords United States	27	1.8k 0.7×	655 0.4×	1.1k 0.8×	345 0.8×	226 0.7×	115	3.0k
Ivana Gojo United States	36	2.5k 0.9×	1.6k 1.1×	2.2k 1.7×	260 0.6×	634 1.9×	136	4.3k
Renate Burger Germany	27	1.6k 0.6×	1.1k 0.8×	990 0.8×	569 1.3×	628 1.9×	66	2.9k
Terry H. Landowski United States	22	1.9k 0.7×	1.7k 1.2×	772 0.6×	511 1.2×	821 2.5×	43	3.4k

Countries citing papers authored by Christine Pien

Since Specialization

Citations

This map shows the geographic impact of Christine Pien's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christine Pien with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christine Pien more than expected).

Fields of papers citing papers by Christine Pien

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christine Pien. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christine Pien. The network helps show where Christine Pien may publish in the future.

Co-authorship network of co-authors of Christine Pien

This figure shows the co-authorship network connecting the top 25 collaborators of Christine Pien. A scholar is included among the top collaborators of Christine Pien based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christine Pien. Christine Pien is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Huang, Zhaohua, Suresh K. Tipparaju, Dmitri B. Kirpotin, et al.. (2019). Formulation optimization of an ephrin A2 targeted immunoliposome encapsulating reversibly modified taxane prodrugs. Journal of Controlled Release. 310. 47–57. 33 indexed citations

2.

Kamoun, Walid S., Lia Luus, Christine Pien, et al.. (2016). Abstract 871: Nanoliposomal targeting of ephrin receptor A2 (EphA2): Preclinical in vitro and in vivo rationale. Cancer Research. 76(14_Supplement). 871–871. 2 indexed citations

3.

Kirpotin, Dmitri B., Suresh K. Tipparaju, Zhaohua Huang, et al.. (2016). Abstract 3912: MM-310, a novel EphA2-targeted docetaxel nanoliposome. Cancer Research. 76(14_Supplement). 3912–3912. 4 indexed citations

4.

Zage, Peter E., Wendy Fang, Christine Pien, et al.. (2010). The selective Trk inhibitor AZ623 inhibits brain‐derived neurotrophic factor–mediated neuroblastoma cell proliferation and signaling and is synergistic with topotecan. Cancer. 117(6). 1321–1391. 24 indexed citations

5.

Fang, Wendy, Riitta Nolo, Sankaranarayanan Kannan, et al.. (2008). Targeting TRKA: Preclinical Evaluation of AZ23 in Acute Myeloid Leukemia. Pediatric Blood & Cancer. 52(6).

6.

Kerrie, L., Everton Mandley, Christine Pien, et al.. (2008). Depilation induced anagen as a model to study hedgehog pathway antagonist IPI-926: Implications for biomarker development. Cancer Research. 68. 2827–2827. 1 indexed citations

7.

Papandreou, Christos N., Danai Daliani, Darrell Nix, et al.. (2004). Phase I Trial of the Proteasome Inhibitor Bortezomib in Patients With Advanced Solid Tumors With Observations in Androgen-Independent Prostate Cancer. Journal of Clinical Oncology. 22(11). 2108–2121. 372 indexed citations

8.

Mitsiades, Constantine, Nicholas Mitsiades, Joseph Negri, et al.. (2004). IPI-504: A Novel hsp90 Inhibitor with In Vitro and In Vivo Anti-Tumor Activity.. Blood. 104(11). 2403–2403. 6 indexed citations

9.

Elliott, Peter J., Teresa A. Soucy, Christine Pien, Julian Adams, & Eric S. Lightcap. (2003). Assays for Proteasome Inhibition. Humana Press eBooks. 85. 163–172. 17 indexed citations

10.

Zollner, Thomas M., Maurizio Podda, Christine Pien, et al.. (2002). Proteasome inhibition reduces superantigen-mediated T cell activation and the severity of psoriasis in a SCID-hu model. Journal of Clinical Investigation. 109(5). 671–679. 9 indexed citations

11.

Zollner, Thomas M., Maurizio Podda, Christine Pien, et al.. (2002). Proteasome inhibition reduces superantigen-mediated T cell activation and the severity of psoriasis in a SCID-hu model. Journal of Clinical Investigation. 109(5). 671–679. 76 indexed citations

12.

Zollner, Thomas M., Maurizio Podda, Christine Pien, et al.. (2002). Proteasome inhibition reduces superantigen-mediated T cell activation and the severity of psoriasis in a SCID-hu model. Journal of Clinical Investigation. 109(5). 671–679. 88 indexed citations

13.

Pien, Christine, et al.. (2002). Characterization of diet induced aortic atherosclerosis in Syrian F1B hamsters. 42(2). 65–83. 3 indexed citations

14.

Orlowski, Robert Z., Thomas E. Stinchcombe, Beverly S. Mitchell, et al.. (2002). Phase I Trial of the Proteasome Inhibitor PS-341 in Patients With Refractory Hematologic Malignancies. Journal of Clinical Oncology. 20(22). 4420–4427. 586 indexed citations breakdown →

15.

LeBlanc, Richard, Laurence Catley, Teru Hideshima, et al.. (2002). Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model.. PubMed. 62(17). 4996–5000. 372 indexed citations

16.

Aghajanian, Carol, Steven L. Soignet, Don S. Dizon, et al.. (2002). A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies.. PubMed. 8(8). 2505–11. 372 indexed citations

17.

Lightcap, Eric S., Teresa A. McCormack, Christine Pien, et al.. (2000). Proteasome Inhibition Measurements: Clinical Application. Clinical Chemistry. 46(5). 673–683. 243 indexed citations

18.

Grisham, Matthew B., Vito J. Palombella, Peter J. Elliott, et al.. (1999). Inhibition of NF-κB activation in vitro and in vivo: Role of 26S proteasome. Methods in enzymology on CD-ROM/Methods in enzymology. 300. 345–363. 80 indexed citations

19.

Elliott, Peter J., et al.. (1999). Proteasome inhibition: A novel mechanism to combat asthma☆☆☆. Journal of Allergy and Clinical Immunology. 104(2). 294–300. 90 indexed citations

20.

Adams, Julian, Vito J. Palombella, Edward A. Sausville, et al.. (1999). Proteasome inhibitors: a novel class of potent and effective antitumor agents.. PubMed. 59(11). 2615–22. 1188 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact